SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Eric Klein who wrote (156)5/6/1997 6:17:00 PM
From: WeirdPro Randy   of 998
 
I think Myotrophin will not initially replace Rilutek, but add to the treatment for ALS. Very simply stated, Rilutek can extend "quantity" of life, while myotrophin improves the "quality" of life.
It is likely that the outcome Thursday will be an approval of myotrophin , with a Phase IV trial of the two together required by the FDA....which is not detrimental to CEPH at all.
A share of CEPH tomorrow will look like gold on Friday.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News